Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?

Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $9.09, but opened at $9.50. Pharming Group shares last traded at $9.64, with a volume of 3,700 shares.

Analyst Ratings Changes

Several brokerages recently issued reports on PHAR. Oppenheimer decreased their price target on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 price target for the company. Finally, HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Stock Down 2.9 %

The firm has a market capitalization of $611.96 million, a price-to-earnings ratio of -34.70 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The stock has a fifty day moving average of $8.99 and a two-hundred day moving average of $8.42.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.